VYNDAQEL caps moll 61 mg 30 pce

7680675180011 CH-67518 N07XX08 01.99.0.

Reimbursement limitations:

VYNDAQEL.01

Traitement de patients atteints de cardiomyopathie amyloïde à transthyrétine (ATTR-CM) de type sauvage ou héréditaire …

VYNDAQEL caps moll 61 mg 30 pce
VYNDAQEL caps moll 61 mg 30 pce
VYNDAQEL caps moll 61 mg 30 pce
1 / 3
google

Details

Product number
6751801
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
tafamidisum 61 mg, macrogolum 400, polysorbatum 20, povidonum K 90, E 321, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (rubrum), Drucktinte: macrogolum 400, polyvinylis acetas phtalas, E 171, propylenglycolum, pro capsula.

Articles (1)

Vyndaqel 61 mg, Weichkapseln
Weichkapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Detailed composition

Substance Quantity Type Category
(N/A)
61.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance ANTOX
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance FTODK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)

Reimbursement information

Public price
CHF 9031.50
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/12/2021

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
67518
Drug name
Vyndaqel 61 mg, Weichkapseln
Galenic form
KAPWE
ATC Code
N07XX08
Authorization status
Z
Dispensation category
B
First authorization
05/03/2020
Authorization expiration date
31/12/9999
IT number
01.99.0.
Domain
Human medicine
Field of application
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie

Packaging details

Description (FR)
VYNDAQEL caps moll 61 mg 30 pce
Description (DE)
VYNDAQEL Weichkaps 61 mg 30 Stk
Market launch
05/03/2020
Narcotic (BTM)
No